Category: Include on Menu
-
Femasys Secures FDA Approval for Modular PMA Pathway for FemBloc
Femasys has received FDA approval to use a modular premarket approval submission process for FemBloc, giving the company a defined regulatory framework as its pivotal U.S. clinical trial continues. Key Investor Takeaways Why FEMY Stock Is in Focus Femasys (NASDAQ:FEMY) has secured FDA approval for a modular premarket approval application pathway for FemBloc, establishing how…
-
QTREX Achieves Direct Graphene-Like Carbon Conversion for Quantum Processor Protection
QTREX has demonstrated a patent-pending process that converts sections of 3D-printed insulation directly into conductive graphene-like carbon, with cryogenic validation and a commercial launch of its DF INSU300 material now among the next milestones. Key Investor Takeaways Why QTEX Stock Is in Focus QTREX (NASDAQ:QTEX) has demonstrated a patent-pending technology that uses localized laser processing…
-
Datavault AI Q2 Revenue Jumps 287% as Tokenization Platform Moves Toward Commercialization
Datavault AI reported $6.7 million in second-quarter revenue and maintained its target of at least $200 million for 2026, putting execution and the conversion of commercial opportunities into recognised revenue firmly in focus. Key Investor Takeaways Why DVLT Stock Is in Focus Datavault AI (NASDAQ:DVLT) delivered 287% year-over-year Q2 revenue growth as it continued assembling…
-
Eshallgo Secures Exclusive North American Distribution Partnership With Zhongshan Senwei
Eshallgo’s California subsidiary will exclusively distribute Zhongshan Senwei printing consumables in North America, initially targeting major e-commerce channels as the company builds its overseas operations. Key Investor Takeaways Why EHGO Stock Is in Focus Eshallgo (NASDAQ:EHGO) is expanding its North American strategy through an exclusive distribution agreement between its wholly owned California subsidiary and Zhongshan…
-
IQSTEL First-Half Revenue Jumps 59% as Digital Services Strategy Takes Focus
IQSTEL generated $207 million in first-half revenue while gross profit growth lagged the top-line increase, putting margin expansion and its $430 million full-year target in focus. Key Investor Takeaways Why IQST Stock Is in Focus IQSTEL (NASDAQ:IQST) delivered 59% year-over-year first-half revenue growth, taking sales to $207 million from approximately $130 million a year earlier.…
-
Lowe’s Cuts Full-Year Sales Outlook as DIY Spending Remains Under Pressure
Lowe’s (NYSE:LOW) has lowered its full-year sales forecast as persistent weakness in spending on major home improvement projects continues to weigh on the retailer, with CEO Marvin Ellison pointing to a challenging environment for discretionary DIY purchases. Shares of Lowe’s fell more than 2% in Wednesday premarket trading following the updated outlook. High interest rates…
-
Target Raises Full-Year Sales Outlook as Turnaround Efforts Gain Traction
Target (NYSE:TGT) has increased its annual sales forecast for a second consecutive quarter, offering further signs that the retailer’s turnaround strategy under new CEO Michael Fiddelke may be beginning to deliver results. Excluding the impact of a tariff refund, Target now expects full-year earnings per share to be $0.75 higher at the midpoint than its…
-
Analog Devices Rises as Third-Quarter Results and Q4 Forecast Top Estimates
Analog Devices (NASDAQ:ADI) shares gained more than 1% in Wednesday premarket trading after the semiconductor company delivered better-than-expected fiscal third-quarter results and issued a fourth-quarter outlook above Wall Street forecasts, supported by strength in its data centre and industrial businesses. For the third quarter, Analog Devices reported earnings per share of $3.45, exceeding the analyst…
-
TJX Shares Fall as Third-Quarter Profit Forecast Misses Expectations
TJX (NYSE:TJX) shares fell around 4% in Wednesday premarket trading after the retailer issued a third-quarter earnings forecast below Wall Street expectations, overshadowing stronger-than-expected quarterly profit and an increase to its full-year guidance. For the second quarter, TJX reported earnings per share of $1.22, ahead of the $1.19 analyst consensus. Revenue reached $15.2 billion, broadly…
-
Moderna Shares Surge More Than 90% After Phase 3 Melanoma Trial Success
Moderna Inc (NASDAQ:MRNA) shares surged more than 90% in Wednesday pre-market trading after the biotechnology company and Merck (NYSE:MRK) reported positive Phase 3 results for their melanoma treatment combination, which performed better than Keytruda alone. The INTerpath-001 study evaluated intismeran autogene, an investigational mRNA-based individualised neoantigen therapy, in combination with Merck’s Keytruda in patients with…